Surrey Heartlands

Joint Formulary & PAD

Dapagliflozin - Chronic Kidney Disease

You are here : Home > Formulary Search > Dapagliflozin - Chronic Kidney Disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :

Documentation

Evidence Review
Dapagliflozin for chronic kidney disease - NICE Briefing - Jun 2022
Patient resource
Getting the most from your SGLT2 inhibitor (gliflozin) medicine - Patient information - Feb 25
Webpage
London Kidney Network resources
Webpage
NICE TA 775 Dapagliflozin for Chronic Kidney Disease Mar 22

PAD Profile

ChemicalSubstance :
Dapagliflozin
Indication :
Chronic Kidney Disease
Group Name :
Keywords :
CKD
Brand Names Include :
Forxiga
Important Information :
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Chronic Kidney Disease
Supporting Documents :
4

Other Indications

Below are listed other indications that Dapagliflozin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Chronic Kidney Disease.

Committee Recommendations (2)

10 Feb 25 - Surrey Heartlands Medicines Safety Committee (MSC)

The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.

01 Jun 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends dapagliflozin for treating chronic kidney disease in line with NICE TA 775.

Dapagliflozin will be considered GREEN on the traffic light system.

Key considerations:
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.